RecruitingNCT06545877
REKOVELLE PEN for S.C. Injection General Drug Use Survey (Controlled Ovarian Stimulation in Assisted Reproductive Technologies)
REKOVELLE® PEN S.C. Injection 12μg/36μg/72μg for Controlled Ovarian Stimulation in Assisted Reproductive Technologies - General Drug Use-results Survey
Sponsor
Ferring Pharmaceuticals
Enrollment
500 participants
Start Date
Sep 16, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
This survey targets controlled ovarian stimulation with this drug for the development of multiple oocytes in women undergoing assisted reproduction (ART) such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).
Eligibility
Sex: FEMALE
Inclusion Criteria1
- Participants who received the REKOVELLE in controlled ovarian stimulation in assisted reproductive technologies and have consented to participate in the survey.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06545877
Related Trials
Measuring Free Radicals in Human Sperm Cells Related to Microbiota and Lifestyle Factors
NCT055142231 location
Interest of Sperm Insemination at 42 Hours Post hCG Compared to 36h in Intrauterine Insemination
NCT068045384 locations
Biorepository in Participants Who Undergo OTC for Gonadotoxic Therapy
NCT054406171 location
Inherited Reproductive Disorders
NCT015004472 locations
Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation
NCT062121022 locations